Greatwall promotes cell transformation by hyperactivating AKT in human malignancies

  1. Jorge Vera
  2. Lydia Lartigue
  3. Suzanne Vigneron
  4. Gilles Gadea
  5. Veronique Gire
  6. Maguy Del Rio
  7. Isabelle Soubeyran
  8. Frederic Chibon
  9. Thierry Lorca
  10. Anna Castro  Is a corresponding author
  1. Université de Montpellier, France
  2. Université Bordeaux Segalen, France
  3. Institut de Recherche en Cancérologie de Montpellier, France

Abstract

The PP2A phosphatase is often inactivated in cancer and is considered as a tumour suppressor. A new pathway controlling PP2A activity in mitosis has been recently described. This pathway includes the Greatwall (GWL) kinase and its substrates endosulfines. At mitotic entry, GWL is activated and phosphorylates endosulfines that then bind and inhibit PP2A. We analysed whether GWL overexpression could participate in cancer development. We show that GWL overexpression promotes cell transformation and increases invasive capacities of cells through hyperphosphorylation of the oncogenic kinase AKT. Interestingly, AKT hyperphosphorylation induced by GWL is independent of endosulfines. Rather, GWL induces GSK3 kinase dephosphorylation in its inhibitory sites and subsequent SCF-dependent degradation of the PHLPP phosphatase responsible for AKT dephosphorylation. In line with its oncogenic activity, we find that GWL is often overexpressed in human colorectal tumoral tissues. Thus, GWL is a human onocoprotein that promotes the hyperactivation of AKT via the degradation of its phosphatase, PHLPP, in human malignancies.

Article and author information

Author details

  1. Jorge Vera

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Lydia Lartigue

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeux, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Suzanne Vigneron

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Gilles Gadea

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Veronique Gire

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Maguy Del Rio

    Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Isabelle Soubeyran

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeaux, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Frederic Chibon

    Department of Medical Oncology, Institut Bergonié, Institut National de la Santé et de la Recherche Medicale, Université Bordeaux Segalen, Bordeaux, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Thierry Lorca

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Anna Castro

    Centre de Recherche de Biochimie Macromoléculaire, Université de Montpellier, Montpellier, France
    For correspondence
    anna.castro@crbm.cnrs.fr
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All animal experiments conformed to the relevant regulatory standards and were approved by the Ethics Local Committee of the IRCM (Institut de Recherche en Cancérologie de Montpellier) and by the Regional Ethic Commitée of the "Languedoc Roussillon"(France). Ref: 1137.

Human subjects: Human Samples for TMA:Cases were issued from the archives of the Department of Pathology of Bergonie Institute (Bordeaux, France). For all samples, ethical approval was obtained from the appropriate committees. Cases were then centralised in the Biological Resources Center of Bergonie Institute, which has received the agreement from the French authorities to deliver samples for scientific research (AC-2008-812)."The TMA used in this study has been moreover used in three other published studies (See: Soubeyran and al., Am J of Pathology 2011, Rey and al., Cell Cycle 2013 and Oncogene 2015).For colorectal tumour samples used for western blot:The study was approved by the ICM CORT (Translational Research Committee) ethical committee and all participating patients were informed of the study and provided their signed written informed consent before enrolment. This set of samples were already used in Del Rio et al., JCO 2007 and Del Rio et al, Plos one 2013.

Copyright

© 2015, Vera et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,745
    views
  • 461
    downloads
  • 45
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jorge Vera
  2. Lydia Lartigue
  3. Suzanne Vigneron
  4. Gilles Gadea
  5. Veronique Gire
  6. Maguy Del Rio
  7. Isabelle Soubeyran
  8. Frederic Chibon
  9. Thierry Lorca
  10. Anna Castro
(2015)
Greatwall promotes cell transformation by hyperactivating AKT in human malignancies
eLife 4:e10115.
https://doi.org/10.7554/eLife.10115

Share this article

https://doi.org/10.7554/eLife.10115

Further reading

    1. Cell Biology
    2. Developmental Biology
    Sofía Suárez Freire, Sebastián Perez-Pandolfo ... Mariana Melani
    Research Article

    Eukaryotic cells depend on exocytosis to direct intracellularly synthesized material toward the extracellular space or the plasma membrane, so exocytosis constitutes a basic function for cellular homeostasis and communication between cells. The secretory pathway includes biogenesis of secretory granules (SGs), their maturation and fusion with the plasma membrane (exocytosis), resulting in release of SG content to the extracellular space. The larval salivary gland of Drosophila melanogaster is an excellent model for studying exocytosis. This gland synthesizes mucins that are packaged in SGs that sprout from the trans-Golgi network and then undergo a maturation process that involves homotypic fusion, condensation, and acidification. Finally, mature SGs are directed to the apical domain of the plasma membrane with which they fuse, releasing their content into the gland lumen. The exocyst is a hetero-octameric complex that participates in tethering of vesicles to the plasma membrane during constitutive exocytosis. By precise temperature-dependent gradual activation of the Gal4-UAS expression system, we have induced different levels of silencing of exocyst complex subunits, and identified three temporarily distinctive steps of the regulated exocytic pathway where the exocyst is critically required: SG biogenesis, SG maturation, and SG exocytosis. Our results shed light on previously unidentified functions of the exocyst along the exocytic pathway. We propose that the exocyst acts as a general tethering factor in various steps of this cellular process.

    1. Cell Biology
    Yue Miao, Yongtao Du ... Mei Ding
    Research Article

    The spatiotemporal transition of small GTPase Rab5 to Rab7 is crucial for early-to-late endosome maturation, yet the precise mechanism governing Rab5-to-Rab7 switching remains elusive. USP8, a ubiquitin-specific protease, plays a prominent role in the endosomal sorting of a wide range of transmembrane receptors and is a promising target in cancer therapy. Here, we identified that USP8 is recruited to Rab5-positive carriers by Rabex5, a guanine nucleotide exchange factor (GEF) for Rab5. The recruitment of USP8 dissociates Rabex5 from early endosomes (EEs) and meanwhile promotes the recruitment of the Rab7 GEF SAND-1/Mon1. In USP8-deficient cells, the level of active Rab5 is increased, while the Rab7 signal is decreased. As a result, enlarged EEs with abundant intraluminal vesicles accumulate and digestive lysosomes are rudimentary. Together, our results reveal an important and unexpected role of a deubiquitinating enzyme in endosome maturation.